A careful review of Kenvue’s EADV findings on sunscreen, colloidal oat and minoxidil, including reported results and practical limits.
On September 30, 2026, Kenvue said Neutrogena, Aveeno and Regaine were presenting 12 scientific data sets at the European Academy of Dermatology and Venereology (EADV) Congress. The meeting took place in Vienna from September 30 to October 3, 2026. The announcement brought together research on sunscreen formulations, colloidal oat and minoxidil across several skin and hair concerns.
The reported findings ranged from changes in visible redness and hydration to skin-barrier proteins and hair counts. For women interested in beauty longevity, the useful story is how these different measurements relate to everyday concerns. They need to be read as distinct pieces of research rather than one combined verdict on the brands.
The clearest biological thread in Kenvue’s announcement concerns the skin barrier. Aveeno-related preclinical and clinical research on an oat-containing lotion reported increased production or preservation of proteins called filaggrin and loricrin. It also reported increased ceramide production alongside improved hydration and faster barrier recovery following UV exposure.
In everyday language, the researchers were examining components associated with the skin’s protective barrier. Rather than looking only at how skin appeared, this work considered changes in barrier-related proteins and ceramides. That gives the findings a different focus from a study measuring visible facial spots or shine.
The sunscreen evaluations looked at appearance and hydration during product use. According to Kenvue, the formulations contained niacinamide alongside other ingredients. The oil-control formulation included trehalose while the hydration formulation included vitamins C and E.
The Regaine analysis focused on hair counts in men with androgenetic alopecia. Its biological outcome was a measured change in hairs rather than a report of how full the hair looked. Together, these studies show why “skin and hair health” needs to be broken into specific outcomes before a claim becomes useful.
Kenvue’s release and Investing.com’s coverage reported results for Neutrogena Ultra Sheer Invisible Fluid Sunscreen Oil Control 50+. The formulation contained 2% trehalose and 2% niacinamide. The evaluation involved two small Brazilian populations with acne-prone and oily skin.
After 28 days, the company reported:
These measurements describe different aspects of skin appearance and hydration. A change in redness is not the same outcome as a change in pigmentation. Likewise, oiliness and hydration were reported separately rather than treated as opposite ends of one measurement.
A separate evaluation studied Neutrogena Ultra Sheer Invisible Fluid Sunscreen Hydration Fluid 50 in women with dry skin. According to Kenvue, this formulation contained 2% niacinamide and vitamins C and E.
The company reported a 22% improvement in hydration after 28 days. It also described improvements in skin tone uniformity and radiance. Reductions in visible facial spots associated with hyperpigmentation were reported through 56 days.
Kenvue also described a survey of 178 dermatologists and pediatric clinicians. Respondents were based in Germany and Italy as well as the United Kingdom and the United States. The questions concerned a colloidal-oat emollient used alongside topical corticosteroids.
The release said 87.6% reported frequently recommending such an emollient. It also said 92.7% reported steroid-sparing or steroid-optimization effects. Here, the percentages describe clinicians’ responses to survey questions.
The Regaine findings came from a post-hoc analysis of a Phase III trial of Regaine 5% Minoxidil Topical Foam. Kenvue reported results in men with androgenetic alopecia over 16 weeks.
The company reported average increases of 23.06 hairs for men with Norwood-Hamilton Type III hair loss. For men with Type IV or V loss, it reported an increase of 18.70 hairs. The release described statistically significant improvement versus placebo across the hair-loss classifications.
The public announcement presents selected conference-abstract findings rather than full study reports. Several evaluations lack sample sizes and important design details. Those omissions limit how confidently the reported results can be interpreted.
For the sunscreen evaluations, the release does not provide enough information about comparison groups or methods to judge how much change was attributable to product use. It does not separate the contribution of individual ingredients from the complete formulation. It also does not establish superiority over other products or lasting benefits beyond the reported follow-up.
The oat research combines preclinical and clinical work without enough protocol or participant information to assess the size and generalizability of its effects. The eczema survey records clinicians’ perceptions and practice rather than controlled patient outcomes. Its response rate and sampling method are not reported.
The minoxidil analysis examined subgroups after the parent trial. It was not a new prospective trial designed to compare age or severity groups directly. The release omits the parent trial’s sample size and relevant analysis details, and these male-only findings do not establish subgroup effects for women.
Real-world results therefore need not match the reported study averages. Younell’s guide to matching a claim to the strength of its evidence provides a broader framework for making these distinctions.
The immediate application is better interpretation, not a new treatment plan. These results offer questions to bring to product choices and qualified care. They do not require rebuilding a routine around the announcement.
Keep the outcome specific. When considering sunscreen research, distinguish hydration findings from changes in visible redness or pigmentation. A percentage tied to one outcome should not become a promise about overall skin improvement. Our discussion of the evidence behind everyday skincare routines offers additional context for evaluating familiar categories.
Assess the formulation rather than the ingredient headline. The sunscreen studies evaluated complete products. The presence of niacinamide or trehalose on another label does not make that product equivalent to the studied formulation. Ingredient recognition is a starting point for questions rather than a substitute for product-specific evidence.
Keep supportive skincare separate from treatment decisions. The colloidal-oat survey concerned an emollient used alongside topical corticosteroids. Personal decisions about eczema care or changing prescribed treatment belong with a qualified clinician. A reported clinician preference is not a reason to adjust medication independently.
Bring hair-treatment questions to qualified care. For women considering options for thinning hair, the Regaine announcement is a research discussion rather than a personal recommendation. A qualified clinician can address whether a treatment is appropriate for an individual situation. The useful next step is an informed conversation rather than adopting a subgroup average as an expected result.
For Younell, beauty longevity means separating useful evidence from marketing noise while keeping long-term wellbeing in view. This announcement brings familiar ingredients into more specific conversations about skin appearance, barrier biology and hair counts. Its value lies in those focused questions rather than a sweeping promise about looking younger.
Will the next wave of beauty research connect these biological measurements with outcomes that matter most in everyday skin and hair care?
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
